Known driver mutations in cSCC are TP53 (early event, <65% of cSCC), NOTCH (early event, <75% of cSCC), CDKN2A (50% of cSCC, with additional epigenetic inactivation), and TGFB1[14], [15], [16]. This evidence concerns the gene TP53 and skin squamous cell carcinoma.